
Published 22 July 2021
As the psychedelic drug market rapidly expands – it’s expected to reach $6.85bn by 2027, from $2.1bn in 2019 (Data Bridge Market Research, 2020) – start-up Eastra Health is pioneering psychedelic-derived medicines for women. The Toronto-based biotech is betting that low-dose formulations targeting the serotonin system can address mental and physical challenges related to menopause and PMS.



Offering access to over 350 consumer and cross-industry reports annually, Stylus Membership is your window to tomorrow’s most exciting opportunities.
We already arm more than 500 of the world’s most forward-thinking brands and agencies with the creative insights they need to make transformative business decisions.
We’d love to do the same for you.
Book a demo with us today to discover more.
Daily (and mounting) challenges are driving people to prioritise pleasure and easy living, and also inspiring a desire for intensity. People are embracing ‘hard mode’ – appreciating effort for effort’s sake while still modulating how and where they exert themselves. We profile this achievement-orientated mindset and how...